Immunomedics Inc. (NASDAQ:IMMU) – Equities research analysts at Jefferies Group issued their Q2 2017 earnings per share estimates for shares of Immunomedics in a report issued on Thursday. Jefferies Group analyst M. Andrews expects that the firm will earn ($0.09) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $5.50 target price on the stock. Jefferies Group also issued estimates for Immunomedics’ Q3 2017 earnings at ($0.08) EPS, Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.35) EPS, FY2018 earnings at ($0.17) EPS, FY2019 earnings at $0.08 EPS and FY2020 earnings at $0.23 EPS.

Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.06.

Earnings History and Estimates for Immunomedics (NASDAQ:IMMU)

A number of other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “strong sell” rating in a research report on Monday, August 22nd. Wells Fargo & Co. lowered shares of Immunomedics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 21st.

Shares of Immunomedics (NASDAQ:IMMU) opened at 2.56 on Monday. The company’s 50-day moving average is $2.97 and its 200-day moving average is $3.04. The company’s market capitalization is $245.42 million. Immunomedics has a one year low of $1.61 and a one year high of $5.44.

Several institutional investors have recently made changes to their positions in the company. Iguana Healthcare Management LLC bought a new position in shares of Immunomedics during the second quarter worth $522,000. Cubist Systematic Strategies LLC bought a new position in shares of Immunomedics during the second quarter worth $161,000. Panagora Asset Management Inc. increased its position in shares of Immunomedics by 12.1% in the second quarter. Panagora Asset Management Inc. now owns 980,444 shares of the biopharmaceutical company’s stock worth $2,275,000 after buying an additional 105,690 shares in the last quarter. State Street Corp increased its position in shares of Immunomedics by 63.3% in the second quarter. State Street Corp now owns 2,354,732 shares of the biopharmaceutical company’s stock worth $5,463,000 after buying an additional 912,372 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Immunomedics by 13.0% in the second quarter. Rhumbline Advisers now owns 115,948 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 13,313 shares during the period. 53.79% of the stock is owned by institutional investors.

In other Immunomedics news, Director Mary E. Paetzold sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $2.98, for a total value of $44,700.00. Following the completion of the transaction, the director now directly owns 82,474 shares of the company’s stock, valued at $245,772.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Don C. Stark sold 9,900 shares of the business’s stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $2.97, for a total transaction of $29,403.00. Following the completion of the transaction, the director now directly owns 55,848 shares of the company’s stock, valued at $165,868.56. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

5 Day Chart for NASDAQ:IMMU

Receive News & Stock Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related stocks with our FREE daily email newsletter.